Malignancies Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Malignancies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 68 trials

Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 2

A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

Acute Myeloid LeukemiaAMLMDS+4 more
Franziska Wachter37 enrolled2 locationsNCT05796570
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Malignancies+1 more
Bristol-Myers Squibb252 enrolled8 locationsNCT07223047
Recruiting
Phase 2

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Hematological Malignancies
Janssen Research & Development, LLC510 enrolled77 locationsNCT04634552
Recruiting
Phase 2

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 1

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Kaposi SarcomaViral Associated MalignanciesEBV/KSHV-associated Lymphomas
National Cancer Institute (NCI)58 enrolled1 locationNCT04902443
Recruiting
Not Applicable

CSF and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and CNS Metastases or no CNS Metastases

Brain MetastasasesSolid Tumor MalignanciesLeptomeningeal Disease (LMD)
Sunnybrook Health Sciences Centre60 enrolled1 locationNCT07476781
Recruiting
Phase 1Phase 2

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Hematologic Malignancies
Sellas Life Sciences Group160 enrolled21 locationsNCT04588922
Recruiting

Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)

LymphomaLymphoid Hematological Malignancies
University of Zurich50 enrolled1 locationNCT07472972
Recruiting
Phase 1Phase 2

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Advanced Solid Malignancies
AstraZeneca695 enrolled33 locationsNCT05417594
Recruiting
Phase 1

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

T-cell Malignancies
Electra Therapeutics Inc.84 enrolled1 locationNCT07465835
Recruiting
Phase 1Phase 2

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT06316856
Recruiting

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Mantle Cell LymphomaSudden Cardiac DeathChronic Lymphocytic Leukemia (CLL)+3 more
National Heart, Lung, and Blood Institute (NHLBI)135 enrolled1 locationNCT05724121
Recruiting
Phase 1Phase 2

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

Hematologic MalignanciesHIV
National Cancer Institute (NCI)265 enrolled1 locationNCT05470491
Recruiting
Phase 1

A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

IDH1-Mutated Malignancies
Servier Bio-Innovation LLC30 enrolled18 locationsNCT07006688
Recruiting
Phase 1Phase 2

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Colorectal CarcinomaNon-small Cell Lung CancerBladder Cancer+4 more
Tasca Therapeutics150 enrolled13 locationsNCT07030257
Recruiting
Phase 1Phase 2

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Ovarian CancerMelanomaT-cell Lymphoma+1 more
BioInvent International AB176 enrolled25 locationsNCT04752826
Recruiting
Not Applicable

Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy

Colorectal (Colon or Rectal) CancerPelvic MalignanciesOncofertility
University of South Florida26 enrolled1 locationNCT07419490
Recruiting
Phase 2

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Chronic Lymphocytic LeukemiaB-cell Malignancies
Curis, Inc.108 enrolled1 locationNCT07271667
Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Smoldering Multiple MyelomaMyelodysplastic SyndromesWaldenstrom Macroglobulinemia+5 more
Dana-Farber Cancer Institute10,000 enrolled7 locationsNCT02269592